To evaluate the efficacy and safety of fenspiridе in patients with acute viral tracheobronchitis.
Material and methods
From February to March 2017, thirty adult patients aged of 18 to 70 years with acute viral tracheobronchitis were enrolled into the randomized, prospective, parallel, controlled trial and distributed into two groups. Fifteen patients were treated with fenspiridе 80 mg t.i.d. in combination with antiviral and symptomatic medications, while fifteen patients in the control group were treated only with antiviral and symptomatic drugs. Criteria of efficacy of treatment included duration and intensity of cough, sputum expectoration, fever, dyspnoe and chest pain within the first 5 days.
All patients completed the trial. In the study group the duration of cough and sputum expectoration was shorter than in the control group (cough: 3.1±0.4 and 4.5±0.5 days, sputum expectoration: 2.1±0.5 and 4.1±0.5 days, respectively, р<0.05). The duration and intenisity of fever, dyspnoe and chest pain were comparable in the two groups.
Treatment with fenspiridеresulted in shortening of cough and sputum expectoration in patients with acute viral tracheobronchitis.
Acute tracheobronchitis, treatment, fenspiridе.